Invasive Fungal Infections in Immunocompromised Patients
A special issue of Journal of Fungi (ISSN 2309-608X). This special issue belongs to the section "Fungal Pathogenesis and Disease Control".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 26
Special Issue Editors
Interests: systemic mastocytosis; acute myeloid leukemia; fungal infections in hematological patients; rare hematological diseases
Special Issues, Collections and Topics in MDPI journals
Interests: diagnosis and treatment of hematological malignancies; management of bacterial, fungal and viral infectious complications in neutropenic patients
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Invasive fungal infections (IFI) are still a relevant pitfall in the treatment of patients with hematological or solid neoplasms and acquired immunodeficiency, or who are cared in intensive care unit (ICU). Newer anticancer drugs, consecutive combination of chemotherapy regimens, expanded indications to cellular therapies have increased the population at risk of developping IFI. More extensive use of immunosuppressive agents and biological therapies, and more sofisticated supportive treatments have extended this risk to non cancer population. As a consequence, revision and applicability of diagnostic criteria for IFI have been discussed by different authors both in the hematological and ICU settings. Clinical suspicion, availability and reliability of microbiological tests, presenting radiological imaging and role of broncoalveolar lavage are still matter of debate.
As indications to antifungal prophylaxis remain limited to extremely selected hematological patients, newer antifungal drugs have been developed and tested in various clinical trials with prophylactic and therapeutic purpose. Nonetheless, drug interactions, adverse events, intolerance and resistance to antifungal treatment may leave some patients with limited therapeutic options.
Literature revision and original data are needed to help clinicians establish a correct diagnosis and the best available antifungal therapy.
Dr. Marianna Criscuolo
Dr. Livio Pagano
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Fungi is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- invasive fungal infections
- antifungal drugs
- allogeneic transplant
- hematological neoplasm
- immunosuppressive agents
- intensive care unit
